![Frontiers | High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19 Frontiers | High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19](https://www.frontiersin.org/files/Articles/704767/fphar-12-704767-HTML/image_m/fphar-12-704767-t002.jpg)
Frontiers | High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KALETRA safely and effec
Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa | PLOS ONE
Bioequivalence Study of Two Fixed Dose Combination Tablet Formulations of Lopinavir and Ritonavir in Healthy Volunteers
![Frontiers | High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19 Frontiers | High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19](https://www.frontiersin.org/files/Articles/704767/fphar-12-704767-HTML/image_m/fphar-12-704767-t004.jpg)
Frontiers | High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19
LOPINAVIR/RITONAVIR MYLAN 1. Product Name 2. Qualitative and Quantitative Composition 3. Pharmaceutical Form 4. Clinical Particu
![Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial - The Lancet HIV Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial - The Lancet HIV](https://www.thelancet.com/cms/attachment/9e2160f1-f0ab-460d-b6f2-54ba0a214318/gr1.gif)
Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial - The Lancet HIV
![Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings | Thorax Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings | Thorax](https://thorax.bmj.com/content/thoraxjnl/59/3/252/F1.large.jpg)
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings | Thorax
Randomised Pharmacokinetic Trial of Rifabutin with Lopinavir/Ritonavir-Antiretroviral Therapy in Patients with HIV-Associated Tuberculosis in Vietnam | PLOS ONE
Randomised Pharmacokinetic Trial of Rifabutin with Lopinavir/Ritonavir-Antiretroviral Therapy in Patients with HIV-Associated Tuberculosis in Vietnam | PLOS ONE
![Ritonavir/Lopinavir and Its Potential Interactions With Psychiatric Medications: A COVID-19 Perspective | Psychiatrist.com Ritonavir/Lopinavir and Its Potential Interactions With Psychiatric Medications: A COVID-19 Perspective | Psychiatrist.com](https://www.psychiatrist.com/PublishingImages/20com02677T1.gif)
Ritonavir/Lopinavir and Its Potential Interactions With Psychiatric Medications: A COVID-19 Perspective | Psychiatrist.com
![PDF] Lopinavir/Ritonavir plus Lamivudine and Abacavir or Zidovudine dose Ratios for Paediatric Fixed-Dose Combinations | Semantic Scholar PDF] Lopinavir/Ritonavir plus Lamivudine and Abacavir or Zidovudine dose Ratios for Paediatric Fixed-Dose Combinations | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/2c44d97f8a986b4311c9e3cdf61ff734036a4cd7/14-Table1-1.png)